Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.
Rigby M, Bennett G, Chen L, Mudd GE, Harrison H, Beswick PJ, Van Rietschoten K, Watcham SM, Scott HS, Brown AN, Park PU, Campbell C, Haines E, Lahdenranta J, Skynner MJ, Jeffrey P, Keen N, Lee K. Rigby M, et al. Among authors: park pu. Mol Cancer Ther. 2022 Dec 2;21(12):1747-1756. doi: 10.1158/1535-7163.MCT-21-0875. Mol Cancer Ther. 2022. PMID: 36112771 Free PMC article.
The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b.
Bodyak ND, Mosher R, Yurkovetskiy AV, Yin M, Bu C, Conlon PR, Demady DR, DeVit MJ, Gumerov DR, Gurijala VR, Lee W, McGillicuddy D, Park PU, Poling LL, Protopova M, Qin L, Stevenson CA, Ter-Ovanesyan E, Uttard A, Xiao D, Xu J, Xu L, Bergstrom DA, Lowinger TB. Bodyak ND, et al. Among authors: park pu. Mol Cancer Ther. 2021 May;20(5):896-905. doi: 10.1158/1535-7163.MCT-20-0183. Epub 2021 Mar 15. Mol Cancer Ther. 2021. PMID: 33722858
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect.
Yurkovetskiy AV, Bodyak ND, Yin M, Thomas JD, Clardy SM, Conlon PR, Stevenson CA, Uttard A, Qin L, Gumerov DR, Ter-Ovanesyan E, Bu C, Johnson AJ, Gurijala VR, McGillicuddy D, DeVit MJ, Poling LL, Protopopova M, Xu L, Zhang Q, Park PU, Bergstrom DA, Lowinger TB. Yurkovetskiy AV, et al. Among authors: park pu. Mol Cancer Ther. 2021 May;20(5):885-895. doi: 10.1158/1535-7163.MCT-20-0166. Epub 2021 Mar 15. Mol Cancer Ther. 2021. PMID: 33722857
Separation of mother and daughter cells.
Park PU, McVey M, Guarente L. Park PU, et al. Methods Enzymol. 2002;351:468-77. doi: 10.1016/s0076-6879(02)51865-6. Methods Enzymol. 2002. PMID: 12073364 Review. No abstract available.
SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V. Deckert J, et al. Among authors: park pu. Clin Cancer Res. 2014 Sep 1;20(17):4574-83. doi: 10.1158/1078-0432.CCR-14-0695. Epub 2014 Jul 1. Clin Cancer Res. 2014. PMID: 24987056
21 results